Recce Pharmaceuticals Ltd. · ASX:RCE
Recce Pharmaceuticals — Investor Presentation (July 2022)
21 slides from Recce Pharmaceuticals's investor presentation, Jul 28, 2022
Slide 1: Corporate Presentation - Aussie Equities Day 2022
Corporate Presentation Aussie Equities Day 2022 July 2022
Slide 2: Disclaimer
Disclaimer DISCLAIMER This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this pre
Slide 3: Management Structure
Management Structure Dr John Prendergast – Chairman James Graham – Chief Executive Officer Michele Dilizia – Chief Scientific Officer BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU) BCom (Entrepreneurship), GAICD BSc (Med Sci), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM US based, current Chairman a
Slide 4: A Versatile Technology Platform
A Versatile Technology Platform R529 • Biotech company developing Anti-infectives targeting both bacterial and viral indications • Strong IP and own manufacturing capability • Qualified Infectious Disease Product designation • 10 years market exclusivity plus fast track approval* • Versatile deliver
Slide 5: Strong Pipeline
Strong Pipeline Over Various Indications and Upcoming Inflection Points Asset Indications Discovery Preclinical Phase I Phase II Phase III Market Size Route of administration Market Size Anti-bacterial programs Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 EU/US/AU Serious/life threatenin
Slide 6: Sepsis – it's a big problem!
Sepsis – it’s a big problem! 48.9 million incident One in three patients 11 million sepsis- who die in hospital cases of sepsis related deaths recorded2 have sepsis3 recorded worldwide1 • Sepsis is a life-threatening inflammatory response to infection that has spread in the body. • Kills more people
Slide 7: Sepsis Treatment Paradigm
Sepsis Treatment Paradigm Impact of delayed antibiotic treatment on odds ratio for mortality1 • Current treatment paradigm relies on: • Introducing broad-spectrum antibiotic(s) • Running antibiograms • Adjusting antibiotics based on antibiogram results Early treatment with the correct antibiotic is
Slide 8: Natural Antibiotics vs Synthetic Anti-Infectives
Natural Antibiotics vs Synthetic Anti-Infectives • Pre-formed natural superbugs. • All Fungi or Bacteria based • “Penicillin allergy is the most common drug allergy and is reported in up to 15 percent of hospitalized patients” 1 • Only as good as what’s found in nature. Natural Antibiotics • Has alw
Slide 9: Independent Study Undertaken on R327 MoA
Independent Study Undertaken on R327 MoA1 327 435 529 By Leading Experts in Bacterial MoA Analysis Stage 1 Stage 2 R327 permeabilizes cell membrane and enters the cell R327 interrupts bacterial cellular energetics via ATP Synthesis Stage 3 Stage 4 Cellular division & non-dividing cell functions are
Slide 10: RECCE 327 Multi-Layered Mechanism of Action
327 435 529 RECCE® 327 Multi-Layered Mechanism of Action1 R327 rapidly & irreversibly R327 affects the assembly of R327 results in the shuts down cellular energetics bacterial cell division complex, decreased formation of the (adenosine triphosphate (ATP) components that require cellular bacterial c
Slide 11: RECCE 327 Activity Against Escherichia coli
RECCE® 327 Activity Against Escherichia coli • E. coli grows fast. Eukaryotic cells growing Without R327 R327 (3,000 ppm) healthy, not affected. • R327 at 3,000 ppm shown to be highly effective against E. coli without affecting growing, healthy eukaryotic cells. • R327 rapidly and irreversibly shuts
Slide 12: RECCE 327 Activity Against Staphylococcus aureus
RECCE® 327 Activity Against Staphylococcus aureus • S. aureus bacterial growth slower than E. coli, not Without R327 R327 (2,300 ppm) affecting eukaryotic cells. • R327 at 2,300 ppm shows to be highly effective against S. aureus without affecting growing, healthy eukaryotic cells. • R327 rapidly and
Slide 13: Phase I Human Clinical Trial
Phase I Human Clinical Trial 120x dose amount* 6,000 mg (& beyond?) • Study to assess IV infusion of RECCE® 327 in 80 healthy male subjects as a single High Dose 80x dose amount* 4,000 mg ✓ 7-10 subjects in each ascending dose. cohort: 2 control, 8 R327 40x dose amount* 2,000 mg ✓ • Randomized, doub
Slide 14: Phase I Human Clinical Trial – 'High Dose'
Phase I Human Clinical Trial – ‘High Dose’ 120x dose amount* High Dose Why 6,000mg (R327) over 1 hour infusion? 7-10 subjects in each cohort: 2 control, 8 R327 6,000 mg • Study objectives broadly achieved – now ‘dose-ceiling’ focused. (& beyond?) • 6,000mg (6 grams) over 1 hour IV is HIGH (double th
Slide 15: Topical RECCE 327 - Phase I/II
Topical RECCE® 327 - Phase I/II Burn wound infections • Phase I/II to assess Topical RECCE® 327 in 20 patients – dosing 3 times/week burn wound infections commenced in Q4 2021. for 2 weeks duration • Sponsored by the South Metropolitan Health Service, Department of Health, Government of Western Aust
Slide 16: Topical RECCE 327 – Phase I/II
Topical RECCE® 327 – Phase I/II Patient examples from ongoing Burn Wound trial • Patients suffered major burn injury. • Multiple bacterial species in and surrounding wound. • Growth swabs with organisms including pathogens from the ESKAPE group of bacteria. Pre-treatment, significant Post R327 treat
Slide 17: Patents
Patents Three families across all major markets Patent Family 1 – Antimicrobial Polymers and Recce’s patent portfolio includes more than 20 issued patents their Compositions and patent applications in the world’s major markets, including Family 1 group relates to the Company’s the United States, Eur
Slide 18: Insourced Manufacturing Capabilities
Insourced Manufacturing Capabilities Wholly owned, automated manufacturing facility in Sydney’s Macquarie Park • Raw materials plentiful and cheap – few $/Kg • No expensive waste – 99.9% product yield • Automated manufacture process taking approximately 1 hour • 500 doses per fully automated run • C
Slide 19: Recce Pharmaceuticals Ltd – Capital Structure
Recce Pharmaceuticals Ltd – Capital Structure 7% Snapshot Tickers ASX:RCE, FSE:R9Q 27% Market Cap (approx.) AUD $156 million Priced at $0.88 Top 20 Shareholder Distribution Cash and deposits AUD $15.8 million 31 March 2022 Outstanding shares 177.65 million Average daily volume 150.97k 58% 3 months D
Slide 20: Investment Summary
Investment Summary Proprietary new class of anti-infectives against bacteria and viruses, protected by Composition of Matter Patent. Fast development plans initially targeting: Sepsis, Burn wounds, Helicobacter pylori and COVID-19. Strong pre-clinical data package demonstrating high bactericidal act
Slide 21: Thank you
Thank you James Graham Managing Director and Chief Executive Officer Recce Pharmaceuticals Ltd ASX:RCE; FSE:R9Q +61 2 9256 2572 james.graham@recce.com.au recce.com.au
Recce Pharmaceuticals — Investor Presentation (July 2022) on 6ix